Rein Therapeutics Files Q1 2025 10-Q
Ticker: RNTX · Form: 10-Q · Filed: May 15, 2025 · CIK: 1420565
| Field | Detail |
|---|---|
| Company | Rein Therapeutics, Inc. (RNTX) |
| Form Type | 10-Q |
| Filed Date | May 15, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, pharmaceuticals, financing, corporate-actions
TL;DR
Rein Therapeutics filed its Q1 2025 10-Q, showing recent financing activities and ongoing agreements.
AI Summary
Rein Therapeutics, Inc. filed a 10-Q for the period ending March 31, 2025. The company, formerly Aileron Therapeutics, Inc., reported on its financial status and business activities. Key events mentioned include a private placement and underwriting agreement in April 2025 and March 2025, respectively, and a Harvard and Dana-Farber agreement from February 28, 2010.
Why It Matters
This filing provides insight into Rein Therapeutics' financial health and recent corporate actions, which are crucial for investors to assess the company's ongoing operations and future prospects.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Rein Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- Q1 2025 — Reporting Period (First quarter of 2025 financial reporting)
- 20250331 — Period End Date (The end date for the reporting period)
- 20250515 — Filing Date (The date the 10-Q was filed with the SEC)
Key Players & Entities
- Rein Therapeutics, Inc. (company) — Filer
- Aileron Therapeutics, Inc. (company) — Former Company Name
- 20250331 (date) — Reporting Period End Date
- 20250515 (date) — Filing Date
- 0001420565 (company) — Central Index Key
- 2834 (industry_code) — Standard Industrial Classification
- 7378021989 (phone_number) — Business Phone
- 20240329 (date) — Date of Name Change
- 20071207 (date) — Date of Former Name Change
- 2025-03-31 (date) — Reporting Period End
FAQ
What was Rein Therapeutics' former name?
Rein Therapeutics, Inc. was formerly known as Aileron Therapeutics, Inc., with a name change effective March 29, 2024.
What is the Standard Industrial Classification code for Rein Therapeutics?
The Standard Industrial Classification code for Rein Therapeutics is 2834, which corresponds to Pharmaceutical Preparations.
When did Rein Therapeutics file its 10-Q for the period ending March 31, 2025?
The 10-Q was filed on May 15, 2025.
What significant event occurred in April 2025 according to the filing?
The filing indicates a Subsequent Event related to a Private Placement occurred between April 1, 2025, and April 30, 2025.
Is there any mention of a Harvard and Dana-Farber agreement?
Yes, the filing references a Harvard and Dana-Farber Agreement dated February 28, 2010.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 15, 2025 regarding Rein Therapeutics, Inc. (RNTX).